TheraTech Inc., 410 Chipeta Way, a drug delivery technology company, has signed a multimillion-dollar equity agreement with the San Yang Group of Korea. In addition to the equity investments, Sam Yang will license and market in Korea pharmaceutical products developed by TheraTech.

Founded in 1985, TheraTech develops novel pharmaceutical products such as transdermal patches and other controlled-release-dosage forms. These systems are designed to control the rate and time course of drug absorption to improve the safety of medications and improve patient convenience and compliance.